

Select Clinical Trials

Hematologic Malignancies, Stem Cell Transplantation and Cellular Therapies

Applicable Disease(s)/Treatment(s)	Study Description	Principal Investigator
Leukemia and Myelodysplasia		
Acute myeloid leukemia <i>Newly diagnosed</i>	Protocol # 17-623: A phase 3 randomized study of crenolanib versus midostaurin administered following induction chemotherapy and consolidation therapy in newly-diagnosed patients with FLT3 mutated acute myeloid leukemia	Richard Stone, MD richard_stone@dfci.harvard.edu 617-632-6028
Acute myeloid leukemia <i>Newly diagnosed</i> <i>Relapsed/refractory</i> Myelodysplastic syndrome <i>High risk</i>	Protocol # 17-056: A phase 1 study of SL-401 in combination with azacitidine and venetoclax in relapsed/refractory acute myeloid leukemia (AML) or in treatment-naïve patients with AML not eligible for standard induction therapy, or in patients with high-risk myelodysplastic syndrome	Andrew Lane, MD, PhD andrew_lane@dfci.harvard.edu 617-632-6028
Acute myeloid leukemia <i>Newly diagnosed</i>	Protocol # 18-351: A phase 1b study of venetoclax in combination with intensive induction and consolidation chemotherapy in treatment-naïve patients with acute myelogenous leukemia	Richard Stone, MD richard_stone@dfci.harvard.edu 617-632-6028
B-cell acute lymphoblastic leukemia <i>Newly diagnosed</i>	Protocol # 17-717: A phase 3 trial to evaluate the efficacy of the addition of inotuzumab ozogamicin (a conjugated anti-CD22 monoclonal antibody) to frontline therapy in young adults (ages 18-39 years) with newly-diagnosed precursor B-cell ALL	Daniel DeAngelo, MD, PhD daniel_deangelo@dfci.harvard.edu 617-632-6028
Acute myeloid leukemia Myelodysplastic syndromes <i>Relapsed/refractory</i>	Protocol # 17-718: A phase 1 study of ipilimumab in combination with decitabine in relapsed or refractory myelodysplastic syndrome/acute myeloid leukemia	Jacqueline Garcia, MD jacqueline_garcia@dfci.harvard.edu 617-632-6028
Acute myeloid leukemia <i>Relapsed/refractory</i>	Protocol # 17-099: A phase 1 study of merestinib in combination with LY2874455 in relapsed or refractory acute myeloid leukemia	Jacqueline Garcia, MD jacqueline_garcia@dfci.harvard.edu 617-632-6028
B-cell acute lymphoblastic leukemia Chronic myeloid leukemia <i>Newly diagnosed</i> <i>Relapsed/refractory</i>	Protocol # 18-170: A phase 1 study of ABL001 in combination with dasatinib and prednisone in patients with BCR-ABL positive (BCRABL+) B-cell acute lymphoblastic leukemia and chronic myeloid leukemia	Marlise Luskin, MD MSCE marlise_luskin@dfci.harvard.edu 617-632-6028
Hairy cell leukemia <i>Newly diagnosed</i>	Protocol # 18-212: A phase 2 study of the BRAF inhibitor, vemurafenib, plus obinutuzumab in patients with previously untreated classical hairy cell leukemia	Eric S. Winer, MD erics_winer@dfci.harvard.edu 617-632-6028
Myelodysplastic syndromes <i>Newly diagnosed</i>	Protocol # 19-109: A phase 3 multicenter, randomized, open label study of APR-246 in combination with azacitidine versus azacitidine alone for the treatment of TP53 mutant myelodysplastic syndrome	David Steensma, MD david_steensma@dfci.harvard.edu 617-632-6028

Lymphoma & CLL

Follicular lymphoma <i>Newly diagnosed</i> <i>Relapsed/refractory</i>	Protocol # 18-311: A multi-cohort phase 1b clinical trial of rituximab in combination with immunotherapy in untreated and previously treated follicular lymphoma	Caron Jacobson, MD caron_jacobson@dfci.harvard.edu 617-632-5847
Non-Hodgkin lymphoma <i>Relapsed/refractory</i>	Protocol # 19-063: A phase 1 multiple ascending dose study of DS-3201b in patients with lymphomas	Eric Jacobsen, MD eric_jacobsen@dfci.harvard.edu 617-632-6633
Classical Hodgkin lymphoma <i>Newly diagnosed</i>	Protocol # 19-113: A phase 2 frontline PET/CT-2 response adapted brentuximab vedotin and nivolumab incorporated and radiation free management of early stage classical Hodgkin lymphoma	Ann LaCasce, MD, MMSc ann_lacacse@dfci.harvard.edu 617-582-9086
Chronic lymphocytic leukemia <i>Newly diagnosed</i>	Protocol # 18-226: A phase 2 study of acalabrutinib, venetoclax, and obinutuzumab (AVO) for initial therapy of chronic lymphocytic leukemia	Matthew Davids, MD, MMSc matthew_davids@dfci.harvard.edu 617-632-6331
Chronic lymphocytic leukemia Small lymphocytic lymphoma Richter's syndrome <i>Relapsed/refractory</i>	Protocol # 18-089: A phase 1/2 study of duvelisib and venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, or Richter's syndrome	Matthew Davids, MD, MMSc matthew_davids@dfci.harvard.edu 617-632-6331
Chronic lymphocytic leukemia Small lymphocytic lymphoma Non-Hodgkin lymphoma <i>Relapsed/refractory</i>	Protocol # 19-021: A phase 1/2 study of oral LOXO-305 in patients with previously treated chronic lymphocytic leukemia/ small lymphocytic lymphoma or non-Hodgkin lymphoma	Jennifer Brown, MD, PhD jennifer_brown@dfci.harvard.edu 617-632-4564

Multiple Myeloma & Waldenström's Macroglobulinemia

Multiple myeloma <i>Relapsed/refractory</i>	Protocol # 17-224: A randomized, controlled, open-label, phase 3 study of melflufen/dexamethasone compared with pomalidomide/dexamethasone for patients with relapsed refractory multiple myeloma who are refractory to lenalidomide	Paul Richardson, MD paul_richardson@dfci.harvard.edu 617-632-2104
Multiple myeloma <i>Relapsed/refractory</i>	Protocol # 17-632: An open-label, multicenter, phase 1 trial evaluating the safety and pharmacokinetics of escalating doses of BFCR4350A in patients with relapsed or refractory multiple myeloma	Jacob P. Laubach, MD, MPP jacobp_laubach@dfci.harvard.edu 617-632-4218
Multiple myeloma <i>Relapsed/refractory</i>	Protocol # 17-653: A phase 1 multicenter, open-label study to assess the safety, pharmacokinetics and preliminary efficacy of CC-92480 in combination with dexamethasone in patients with relapsed and refractory multiple myeloma	Paul Richardson, MD paul_richardson@dfci.harvard.edu 617-632-2104
Multiple myeloma <i>Relapsed/refractory</i>	Protocol # 19-291: A phase 1/2 study of twice weekly ixazomib plus pomalidomide and dexamethasone in relapsed or refractory multiple myeloma	Omar Nadeem, MD omar_nadeem@dfci.harvard.edu 617-632-4952
Multiple myeloma <i>Relapsed/refractory</i>	Protocol # 19-719: Myeloma-developing regimens using genomics (MyDRUG) (Genomics guided multi-arm trial of targeted agents alone or in combination with a backbone regimen)	Giada Bianchi, MD giada_bianchi@dfci.harvard.edu 412-735-6279
Multiple myeloma <i>Smoldering</i>	Protocol # 17-212: A phase 2 study of the CD38 antibody daratumumab in patients with high-risk MGUS and low-risk smoldering multiple myeloma	Irene Ghobrial, MD irene_ghobrial@dfci.harvard.edu 617-632-4198
Waldenström's macroglobulinemia <i>Relapsed</i>	Protocol # 19-305: Dasatinib in patients with Waldenström's macroglobulinemia (WM) progressing on ibrutinib	Jorge Castillo, MD jorge_castillo@dfci.harvard.edu 617-632-6045
Waldenström's macroglobulinemia <i>Relapsed</i>	Protocol # 19-474: A single-arm, expanded access study of zanubrutinib (BGB-3111) in patients with B-cell malignancies	Jorge Castillo, MD jorge_castillo@dfci.harvard.edu 617-632-6045

Stem Cell Transplantation		
Transplant conditioning for allogeneic stem cell transplant for myeloid malignancies	Protocol # 18-283: A phase 1 study of venetoclax added to busulfan and fludarabine reduced intensity conditioning regimen for AML, MDS, and MDS/MPN overlap syndromes	Jacqueline Garcia, MD jacqueline_garcia@dfci.harvard.edu 617-632-1906
Relapse treatment	Protocol # 19-265: A phase 1 trial of CIML NK cell infusion for myeloid disease relapse after haploidentical hematopoietic cell transplantation	Rizwan Romee, MD rizwan_romeo@dfci.harvard.edu 617-632-3470
Relapse treatment	Protocol # 19-142: A phase 1 trial of CD25/Treg-depleted DLI plus ipilimumab for myeloid disease relapse after matched-HCT	John Koreth, MBBS, DPhil john_koreth@dfci.harvard.edu 617-632-3470
Relapse treatment and prevention	Protocol #12-217: A randomized placebo-controlled phase 2 trial of irradiated, adenovirus vector transfected GM-CSF secreting autologous leukemia cell vaccination (GVAX) versus placebo vaccination in patients with advanced MDS/AML after allogeneic hematopoietic stem cell transplantation	Vincent Ho, MD vincent_ho@dfci.harvard.edu 617-632-5938
Graft-versus-host disease treatment and prevention	Protocol #18-700: A phase 1b/2 open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AMG 592 in adult patients with steroid refractory chronic graft-versus-host disease	John Koreth, MBBS, DPhil john_koreth@dfci.harvard.edu 617-632-6028
Graft-versus-host disease prevention	Protocol # 18-270: A phase 2 study of ex vivo TCR $\alpha\beta$ T cell depletion for graft-versus-host disease (GVHD) prophylaxis in mismatched donor peripheral blood stem cell transplantation for hematologic malignancies	Vincent Ho, MD vincent_ho@dfci.harvard.edu 617-632-5938
Cellular Therapies		
Diffuse large B-cell lymphoma <i>Relapsed/refractory</i>	Protocol # 19-309: A prospective, multicenter, open-label, single arm, phase 2 study to evaluate the safety and efficacy of defibrotide in the prevention of chimeric antigen receptor-T-cell-associated neurotoxicity in patients with relapsed or refractory diffuse large B-cell lymphoma receiving axicabtagene ciloleucel	Caron Jacobson, MD caron_jacobson@dfci.harvard.edu 617-632-5847
Diffuse large B-cell lymphoma <i>Relapsed/refractory</i>	Protocol # 18-509: A phase 1/2 multicenter study evaluating the safety and efficacy of axicabtagene ciloleucel in combination with utomilumab in patients with refractory large B-cell lymphoma	Caron Jacobson, MD caron_jacobson@dfci.harvard.edu 617-632-5847
Non-Hodgkin lymphoma B-cell acute lymphoblastic leukemia <i>Relapsed/refractory</i>	Protocol # 18-608: A phase 1/2a, open-label, dose-escalation, dose-expansion, parallel assignment study to evaluate the safety and clinical activity of PBCAR0191 in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) and r/r B-cell acute lymphoblastic leukemia (B-ALL)	Caron Jacobson, MD caron_jacobson@dfci.harvard.edu 617-632-5847
Solid tumors Lymphoma <i>Metastatic, relapsed/refractory</i>	Protocol # 19-179: A phase 1/1b open-label multicenter study to characterize the safety and tolerability of TRQ15-01 in patients with relapsed/refractory solid tumors and lymphomas	Sarah Nikiforow, MD, PhD sarah_nikiforow@dfci.harvard.edu

The above-listed trials are a sampling of our many open and accruing studies. If you are interested in, or would like more information about, a clinical trial listed here, please contact the principal investigator.

For a broader listing of our treatment protocols, please visit dfbwcc.org/clinicaltrials.

These trials are conducted through Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center.